Medicus Cuts Planned Teverelix Trial Enrollment by Two-Thirds
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) plans to test its Teverelix drug candidate in about 126 patients after receiving FDA feedback and central ethics approval for a redesigned …
Medicus Cuts Planned Teverelix Trial Enrollment by Two-Thirds Read More